Pending.ai is an artificial intelligence company offering software for the designing, making, and testing drugs to treat disease that is headquartered in Wollongong, Australia and was founded in 2018 by Jingjing Guo and Mark Waller. The Pending.ai platform is made to augment the cognitive abilities of individual scientists and research teams using the company's artificial intelligence models based on high-quality evidence-based drug design solutions.
According to the company's website, the pending.ai drug discovery and development platform uses information on 138 million compounds, data on 21 million reactions, and 146,000 proteins to help researchers make more informed decisions. The platform is made to aid researchers in de novo drug design, structure-based drug design, high-throughput chemistry, and synthesis planning through their Generative Drug Designer and Retrosynthesis Engine.
The structure-based design features of Pending.ai simulate the docking of virtual molecules to simulated proteins and predict how those molecules will alter the proteins function. Synthesis planning features offers by Pending.ai help researchers discovery novel and efficient drug synthesis routes based on computational chemistry models enhanced with artificial intelligence.